Kuznicki Law is investigating the proposed sale of Regulus Therapeutics Inc. (NasdaqCM: RGLS) to Novartis AG. Under the terms of the proposed transaction, shareholders of Regulus will receive $7.00 per share in cash and a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus’ lead product candidate, farabursen. The firm is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Please note that the transaction is structured as a tender offer, such that time may be of the essence.